Figures
- FIGURE 1
Oncoprints of concurrent genetic alterations detected in a) pre-afatinib treatment patients (n=32) and b) post-afatinib treatment patients (n=41). SCLC: small cell lung cancer; PFS: progression-free survival; OS: overall survival; PR: partial response; SD: stable disease; PD: progressive disease.
- FIGURE 2
Oncoprints for resistance mechanisms in 41 patients after afatinib treatment. PFS: progression-free survival; OS: overall survival; TMB: tumour mutation burden; SCLC: small cell lung cancer; PR: partial response; SD: stable disease; PD: progressive disease; ND: not detected.
- FIGURE 3
Kaplan–Meier curves of post-progression survival (PPS) in 41 patients with (+) or without (−) a) EGFR p.T790M, b) APC alterations, c) ALK mutations, d) MET amplification, e) TP53 mutations and f) EGFR amplification.
- FIGURE 4
Kaplan–Meier curves of overall survival (OS) in 41 patients with or without a) EGFR p.T790M, b) APC alterations, c) ALK mutations, d) MET amplification, e) TP53 mutations and f) EGFR amplification.
Tables
- TABLE 1
Factors associated with the successful obtainment of NGS from FFPE specimens
Total specimens Success for NGS analysis Failure for NGS analysis p-value Specimens, n 106 73 33 Timepoint of taking tissues 0.470 Pre-treatment specimen 44 (41.5) 32 (43.8) 12 (36.4) Post-treatment specimen 62 (58.5) 41 (56.2) 21 (63.6) Biopsy sites 0.274 Lung 52 (49.1) 37 (50.7) 15 (45.5) Pleura 10 (9.4) 6 (8.2) 4 (12.1) Mediastinal lymph node 8 (7.5) 4 (5.5) 4 (12.1) Neck lymph node 5 (4.7) 4 (5.5) 1 (3.0) Brain 8 (7.5) 6 (8.2) 2 (6.1) Soft tissue 7 (6.6) 6 (8.2) 1 (3.0) Liver 6 (5.7) 4 (5.5) 2 (6.1) Bone 5 (4.7) 1 (1.4) 4 (12.1) Pleural effusion (cell block) 4 (3.8) 4 (5.5) 0 Adrenal gland 1 (0.9) 1 (1.4) 0 Modality for taking tissues 0.031* Surgery (VATS or excisional biopsy) 51 (48.1) 39 (53.4) 12 (36.4) CT-guided biopsy 21 (19.8) 15 (20.5) 6 (18.2) Echo-guided biopsy 18 (17.0) 13 (17.8) 5 (15.2) Bronchoscopy (including EBUS-TBNA) 16 (15.1) 6 (8.2) 10 (30.3) Tissue preservation time 0.845 ≤2 years 40 (37.7) 28 (38.4) 12 (36.4) >2 years 66 (62.3) 45 (61.6) 21 (63.6) Data presented as n (%), unless otherwise indicated. NGS: next-generation sequencing; FFPE: formalin-fixed paraffin-embedded; VATS: video-assisted thoracic surgery; CT: computed tomography; EBUS-TBNA: endobronchial ultrasound-guided transbronchial needle aspiration. *: p<0.05.
- TABLE 2
Characteristics of the enrolled patients
Total population NGS subgroup Patients, n 362 56 Median age (range), years 61.8 (28–89) 59.5 (28–89) Female 213 (58.8) 33 (58.9) Never-smokers 257 (71.0) 40 (71.4) ECOG 0–1 332 (91.7) 53 (94.6) Co-existence with other malignancies 22 (6.1) 1 (1.8) Tumour relapse (previous stage ≤IIIA) 70 (19.3) 12 (23.2) Metastatic sites Bone 145 (40.1) 20 (35.7) Lung 144 (39.8) 17 (30.4) Brain 110 (30.4) 16 (28.6) Pleural seeding or effusion 101 (27.9) 15 (26.8) Liver 26 (7.2) 2 (3.6) Adrenal gland 16 (4.4) 3 (5.4) EGFR mutation type Common mutations 281 (77.6) 42 (75.0) Exon 19 deletion 194 (53.6) 26 (46.4) p.L858R 85 (23.5) 16 (28.6) p.L858R+exon 19 deletion 3 (0.8) 0 Common/uncommon mutations 16 (4.4) 4 (7.1) Uncommon mutations 65 (18.0) 10 (17.9) Tumour response to afatinib Partial response: 265 (73.2) 44 (78.6) for common mutations 217/281 (77.2) 35/42 (83.3) for common/uncommon mutations 11/16 (68.8) 3/4 (75.0) for uncommon mutations 37/65 (56.9) 6/10 (60.0) Stable disease 64 (17.7) 10 (17.9) Progressive disease 33 (9.1) 2(3.6) Data presented as n (%) or n/N (%), unless otherwise indicated. NGS: next-generation sequencing; ECOG: Eastern Cooperative Oncology Group; EGFR: epidermal growth factor receptor.
Supplementary Material
Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.
Supplementary material 00676-2023.SUPPLEMENT
